Were There Any Silver Linings in GlaxoSmithKline Stock's Earnings Failure?
It was a rough quarter for GlaxoSmithKline. Were there any silver linings?
There's no sugar-coating it: GlaxoSmithKline (NYSE:GSK) had a pretty rough second quarter. U.S. sales of aging blockbuster Advair dropped by an astounding 19%, and Breo and Anora Ellipta, which have been hailed as potential blockbusters, turned in disappointing sales (5 million pounds each in the U.S.). Watch the video below for a quick take on earnings from Motley Fool health care analysts Michael Douglass and David Williamson.